AUSTRALIA
info@sudapharma.com
Facebook
Twitter
Linkedin
YouTube
+61 8 6142 5555
Menu
About Us
Snapshot
Our People
Leadership Team
Management Team
Corporate Governance and Charters
Technology
Products
Zolpimist™ – Treatment for Insomnia
R&D
i
NKT cell therapy Licence from Imperial College London
Anagrelide: Treatment for Cancer
Sumatriptan: Treatment for Migraine
Cannabinoids (CBD)
Publications
i
NKT Publications
Investors
ASX Announcements
Presentations
Analyst Reports
Media
Contact Us
Annual Reports
30 June 2018
30 June 2017
30 June 2016
Recent Agreements
Latest SUDA Investor Presentation>>
ASX Announcements
14 Jul 21
Notification regarding unquoted
29 Jun 21
Application for quotation of securities – SUD
22 Jun 21
Proposed issue of securities – SUD
22 Jun 21
SUDA Placement Raises $3.65m
22 Jun 21
Proposed issue of securities – SUD
